Brief: Deciphera Pharmaceuticals Announces Oral Presentation Of Results From Phase 3 Study of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor
03/06/2024 14:35
June 3 (Reuters) - Deciphera Pharmaceuticals Inc
DCPH.O :
* DECIPHERA PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION OF
RESULTS
FROM MOTION PIVOTAL PHASE 3 STUDY OF VIMSELTINIB IN PATIENTS
WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT) AT 2024 ASCO ANNUAL
MEETING AND ONLINE PUBLICATION IN LANCET
* DECIPHERA PHARMACEUTICALS INC: EXPECTS TO SUBMIT NEW DRUG
APPLICATION IN Q2 OF 2024 & MARKETING AUTHORISATION APPLICATION
IN Q3 OF 2024
Source text for Eikon: ID:nBwb5fMCta
Further company coverage: DCPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Deciphera Pharmaceuticals
See all newsBrief: Deciphera Pharmaceuticals Announces Oral Presentation Of Results From Phase 3 Study of Vimseltinib In Patients With Tenosynovial Giant Cell Tumor
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Deals of the day-Mergers and acquisitions